Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers
Open Access
- 16 April 2007
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 204 (5) , 1049-1056
- https://doi.org/10.1084/jem.20062566
Abstract
We describe a mouse model of fetal loss in factor V Leiden (FvL) mothers in which fetal loss is triggered when the maternal prothrombotic state coincides with fetal gene defects that reduce activation of the protein C anticoagulant pathway within the placenta. Fetal loss is caused by disruption of placental morphogenesis at the stage of labyrinth layer formation and occurs in the absence of overt placental thrombosis, infarction, or perfusion defects. Platelet depletion or elimination of protease-activated receptor 4 (Par4) from the mother allows normal placentation and prevents fetal loss. These findings establish a cause–effect relationship for the observed epidemiologic association between maternal FvL status and fetal loss and identify fetal gene defects as risk modifiers of pregnancy failure in prothrombotic mothers. Pregnancy failure is mediated by Par4-dependent activation of maternal platelets at the fetomaternal interface and likely involves a pathogenic pathway independent of occlusive thrombosis. Our results further demonstrate that the interaction of two given thrombosis risk factors produces markedly disparate consequences on disease manifestation (i.e., thrombosis or pregnancy loss), depending on the vascular bed in which this interaction occurs.Keywords
This publication has 41 references indexed in Scilit:
- Extraembryonic expression of EPCR is essential for embryonic viabilityBlood, 2005
- IN FOCUS: Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case–control ‘NOHA first’ studyJournal of Thrombosis and Haemostasis, 2005
- Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilitiesJournal of Clinical Investigation, 2005
- The use of LMWH in pregnancies at risk: new evidence or perception?Journal of Thrombosis and Haemostasis, 2005
- The long and winding road ... towards LMWH for pregnancy lossJournal of Thrombosis and Haemostasis, 2005
- Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE‐ENOX studyJournal of Thrombosis and Haemostasis, 2004
- Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorderBlood, 2004
- The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysisThrombosis and Haemostasis, 2004
- Thrombin‐induced platelet endostatin release is blocked by a proteinase activated receptor‐4 (PAR4) antagonistBritish Journal of Pharmacology, 2001
- A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.Journal of Clinical Investigation, 1998